Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Design and development of novel, potent and brain penetrant cyclic LRRK2 inhibitors for the treatment of Parkinson's disease.

Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder, where disease-modifying therapy (DMT) represents a major unmet clinical need. Advances in the understanding of underlying pathogenesis reveal the potential therapeutic value of inhibitors targeting leucine-rich repeat kinase 2 (LRRK2...

Wen-Qing Xu, Tian-Qiang Liu, Xin-Yuan Miao et al. · 0 citations
Review Open access Aug 2026

Small-molecule inhibitors targeting the NLRP3 inflammasome: advances since mid-2023 and future perspectives.

This review summarizes recent advances in NLRP3 inflammasome inhibitors reported from mid-2023 to the beginning of 2026, with emphasis on clinical development status, patent landscapes, and structural classifications.

D. Jia, Yun-Lei Hou, Yue Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.